GlassScriptPhysician profile
Iris T Kennedy
NPI 1609954148
$22,472.67
in general payments reported to CMS, 2019-2025
32 companies · $6,814 in 2025
The $6,814 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,371 · 2022: $3,838 · 2023: $4,370 · 2024: $6,080 · 2025: $6,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,860 · Consulting Fee: $5,078 · Honoraria: $1,914 · Travel and Lodging: $1,249 · Gift: $83.25 · Education: $79.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,860.36 |
| Consulting Fee | $5,077.50 |
| Honoraria | $1,914.08 |
| Travel and Lodging | $1,248.70 |
| Gift | $83.25 |
| Education | $79.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $7,097.14 | 2021-2025 | |
| Accord Healthcare, INC. | $2,453.87 | 2023-2025 | |
| Janssen Biotech, INC. | $2,235.02 | 2021-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $1,382.70 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $1,211.25 | 2021-2025 | Myrisk, Prolaris |
| Myovant Sciences INC. | $1,190.74 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $1,176.28 | 2021-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $1,104.90 | 2022-2025 | Erleada |
| Astellas Pharma US INC | $1,096.31 | 2021-2024 | Xtandi |
| Pfizer INC. | $537.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $476.52 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $371.08 | 2023-2025 | Trelstar, Tlando |
| Abbvie INC. | $319.02 | 2021-2025 | |
| Antares Pharma, INC. | $260.31 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Rochester Medical Corporation | $200.04 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $182.00 | 2021-2025 | Keytruda |
| Blue Earth Diagnostics | $158.33 | 2021-2024 | |
| Amgen INC. | $156.56 | 2021-2023 | Xgeva |
| Axonics, INC. | $134.03 | 2021-2023 | Axonics |
| Endo Pharmaceuticals INC. | $99.42 | 2024 | Xiaflex |
| Tolmar, INC. | $86.51 | 2024-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $78.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $69.49 | 2021-2024 | Lynparza |
| Urogen Pharma, INC. | $68.18 | 2021-2025 | |
| Teleflex LLC | $66.87 | 2023 | Urolift |
| Caris Mpi, INC. | $62.42 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $60.11 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $39.97 | 2022 | |
| Allergan, INC. | $39.05 | 2021 | |
| Urovant Sciences INC | $28.45 | 2022 | |
| Procept Biorobotics Corporation | $16.04 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.